| Dr Jean-luc Michel, MD | |
|
29135 Ryan Rd Ste E, Warren, MI 48092-4282 | |
| (248) 951-8928 | |
| (248) 951-2978 |
| Full Name | Dr Jean-luc Michel |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 43 Years |
| Location | 29135 Ryan Rd Ste E, Warren, Michigan |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1457302747 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208D00000X | General Practice | 4301111024 (Michigan) | Primary |
| 208D00000X | General Practice | 10432 (Puerto Rico) | Secondary |
| Entity Name | Vpa Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1336153295 PECOS PAC ID: 9234041948 Enrollment ID: O20031103000102 |
News Archive
Patients with renal disease who live more than 100 km from their nearest peritoneal dialysis unit face a higher risk for peritonitis, particularly with Staphylococcus aureus, than their peers who live closer, results of a large Australian study show.
The Senate's $19.2 billion pay fix was approved by unanimous consent Wednesday and now will go to the House, where it is expected to gain passage before Congress leaves Washington for the holidays. The measure is paid for by a tweak in the health overhaul law.
LMBRI LLC and Lipopharma Therapeutics SL today announced collaboration aimed at transforming cancer drug development and improving patient outcomes. Lipopharma developed new assessment approaches, methods and technologies for developing cancer therapeutics and diagnostics using their proprietary design of structure-based molecules that regulate the structure and functions of the membrane lipids, instead targeting cellular proteins, called "Membrane Lipid-Therapy".
Cell Therapeutics, today announced that the Office of New Drugs of the U.S. Food and Drug Administration after carefully reviewing the materials CTI submitted in support of its appeal, the reviews of the New Drug Application for pixantrone prepared by the FDA staff, the transcript of the March 22, 2010 Oncology Drugs Advisory Committee meeting and consulting with the Center for Drug Evaluation and Research's Deputy Director of Clinical Science and the Office of Biostatistics, concluded that accelerated approval of pixantrone NDA 022481 may not necessarily be out of reach based on a single controlled clinical trial, provided two key matters can be satisfactorily resolved.
› Verified 8 days ago
| Entity Name | Iah Of Michigan Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1578969705 PECOS PAC ID: 9739404666 Enrollment ID: O20150217000587 |
News Archive
Patients with renal disease who live more than 100 km from their nearest peritoneal dialysis unit face a higher risk for peritonitis, particularly with Staphylococcus aureus, than their peers who live closer, results of a large Australian study show.
The Senate's $19.2 billion pay fix was approved by unanimous consent Wednesday and now will go to the House, where it is expected to gain passage before Congress leaves Washington for the holidays. The measure is paid for by a tweak in the health overhaul law.
LMBRI LLC and Lipopharma Therapeutics SL today announced collaboration aimed at transforming cancer drug development and improving patient outcomes. Lipopharma developed new assessment approaches, methods and technologies for developing cancer therapeutics and diagnostics using their proprietary design of structure-based molecules that regulate the structure and functions of the membrane lipids, instead targeting cellular proteins, called "Membrane Lipid-Therapy".
Cell Therapeutics, today announced that the Office of New Drugs of the U.S. Food and Drug Administration after carefully reviewing the materials CTI submitted in support of its appeal, the reviews of the New Drug Application for pixantrone prepared by the FDA staff, the transcript of the March 22, 2010 Oncology Drugs Advisory Committee meeting and consulting with the Center for Drug Evaluation and Research's Deputy Director of Clinical Science and the Office of Biostatistics, concluded that accelerated approval of pixantrone NDA 022481 may not necessarily be out of reach based on a single controlled clinical trial, provided two key matters can be satisfactorily resolved.
› Verified 8 days ago
| Entity Name | Alma Care Visiting Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1518419043 PECOS PAC ID: 6800170788 Enrollment ID: O20170222000849 |
News Archive
Patients with renal disease who live more than 100 km from their nearest peritoneal dialysis unit face a higher risk for peritonitis, particularly with Staphylococcus aureus, than their peers who live closer, results of a large Australian study show.
The Senate's $19.2 billion pay fix was approved by unanimous consent Wednesday and now will go to the House, where it is expected to gain passage before Congress leaves Washington for the holidays. The measure is paid for by a tweak in the health overhaul law.
LMBRI LLC and Lipopharma Therapeutics SL today announced collaboration aimed at transforming cancer drug development and improving patient outcomes. Lipopharma developed new assessment approaches, methods and technologies for developing cancer therapeutics and diagnostics using their proprietary design of structure-based molecules that regulate the structure and functions of the membrane lipids, instead targeting cellular proteins, called "Membrane Lipid-Therapy".
Cell Therapeutics, today announced that the Office of New Drugs of the U.S. Food and Drug Administration after carefully reviewing the materials CTI submitted in support of its appeal, the reviews of the New Drug Application for pixantrone prepared by the FDA staff, the transcript of the March 22, 2010 Oncology Drugs Advisory Committee meeting and consulting with the Center for Drug Evaluation and Research's Deputy Director of Clinical Science and the Office of Biostatistics, concluded that accelerated approval of pixantrone NDA 022481 may not necessarily be out of reach based on a single controlled clinical trial, provided two key matters can be satisfactorily resolved.
› Verified 8 days ago
| Entity Name | Macomb Medical And Wellness Center Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1356876106 PECOS PAC ID: 1557633021 Enrollment ID: O20170817002443 |
News Archive
Patients with renal disease who live more than 100 km from their nearest peritoneal dialysis unit face a higher risk for peritonitis, particularly with Staphylococcus aureus, than their peers who live closer, results of a large Australian study show.
The Senate's $19.2 billion pay fix was approved by unanimous consent Wednesday and now will go to the House, where it is expected to gain passage before Congress leaves Washington for the holidays. The measure is paid for by a tweak in the health overhaul law.
LMBRI LLC and Lipopharma Therapeutics SL today announced collaboration aimed at transforming cancer drug development and improving patient outcomes. Lipopharma developed new assessment approaches, methods and technologies for developing cancer therapeutics and diagnostics using their proprietary design of structure-based molecules that regulate the structure and functions of the membrane lipids, instead targeting cellular proteins, called "Membrane Lipid-Therapy".
Cell Therapeutics, today announced that the Office of New Drugs of the U.S. Food and Drug Administration after carefully reviewing the materials CTI submitted in support of its appeal, the reviews of the New Drug Application for pixantrone prepared by the FDA staff, the transcript of the March 22, 2010 Oncology Drugs Advisory Committee meeting and consulting with the Center for Drug Evaluation and Research's Deputy Director of Clinical Science and the Office of Biostatistics, concluded that accelerated approval of pixantrone NDA 022481 may not necessarily be out of reach based on a single controlled clinical trial, provided two key matters can be satisfactorily resolved.
› Verified 8 days ago
| Entity Name | Michigan Integrative Health Center, Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1922630490 PECOS PAC ID: 3173953288 Enrollment ID: O20200413002700 |
News Archive
Patients with renal disease who live more than 100 km from their nearest peritoneal dialysis unit face a higher risk for peritonitis, particularly with Staphylococcus aureus, than their peers who live closer, results of a large Australian study show.
The Senate's $19.2 billion pay fix was approved by unanimous consent Wednesday and now will go to the House, where it is expected to gain passage before Congress leaves Washington for the holidays. The measure is paid for by a tweak in the health overhaul law.
LMBRI LLC and Lipopharma Therapeutics SL today announced collaboration aimed at transforming cancer drug development and improving patient outcomes. Lipopharma developed new assessment approaches, methods and technologies for developing cancer therapeutics and diagnostics using their proprietary design of structure-based molecules that regulate the structure and functions of the membrane lipids, instead targeting cellular proteins, called "Membrane Lipid-Therapy".
Cell Therapeutics, today announced that the Office of New Drugs of the U.S. Food and Drug Administration after carefully reviewing the materials CTI submitted in support of its appeal, the reviews of the New Drug Application for pixantrone prepared by the FDA staff, the transcript of the March 22, 2010 Oncology Drugs Advisory Committee meeting and consulting with the Center for Drug Evaluation and Research's Deputy Director of Clinical Science and the Office of Biostatistics, concluded that accelerated approval of pixantrone NDA 022481 may not necessarily be out of reach based on a single controlled clinical trial, provided two key matters can be satisfactorily resolved.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Jean-luc Michel, MD 29135 Ryan Rd Ste E, Warren, MI 48092-4282 Ph: (248) 951-8928 | Dr Jean-luc Michel, MD 29135 Ryan Rd Ste E, Warren, MI 48092-4282 Ph: (248) 951-8928 |
News Archive
Patients with renal disease who live more than 100 km from their nearest peritoneal dialysis unit face a higher risk for peritonitis, particularly with Staphylococcus aureus, than their peers who live closer, results of a large Australian study show.
The Senate's $19.2 billion pay fix was approved by unanimous consent Wednesday and now will go to the House, where it is expected to gain passage before Congress leaves Washington for the holidays. The measure is paid for by a tweak in the health overhaul law.
LMBRI LLC and Lipopharma Therapeutics SL today announced collaboration aimed at transforming cancer drug development and improving patient outcomes. Lipopharma developed new assessment approaches, methods and technologies for developing cancer therapeutics and diagnostics using their proprietary design of structure-based molecules that regulate the structure and functions of the membrane lipids, instead targeting cellular proteins, called "Membrane Lipid-Therapy".
Cell Therapeutics, today announced that the Office of New Drugs of the U.S. Food and Drug Administration after carefully reviewing the materials CTI submitted in support of its appeal, the reviews of the New Drug Application for pixantrone prepared by the FDA staff, the transcript of the March 22, 2010 Oncology Drugs Advisory Committee meeting and consulting with the Center for Drug Evaluation and Research's Deputy Director of Clinical Science and the Office of Biostatistics, concluded that accelerated approval of pixantrone NDA 022481 may not necessarily be out of reach based on a single controlled clinical trial, provided two key matters can be satisfactorily resolved.
› Verified 8 days ago
Paula E Williamson, MD General Practice Medicare: Not Enrolled in Medicare Practice Location: 11477 East 12 Mile Road, Warren, MI 48093 Phone: 586-751-0200 Fax: 586-751-0414 | |
Mr. Barry Michael Crawford, D.O. General Practice Medicare: Medicare Enrolled Practice Location: 12640 E 12 Mile Rd, Warren, MI 48093 Phone: 586-751-2020 Fax: 586-745-1756 | |
Moniruzzaman Khan, MD General Practice Medicare: Accepting Medicare Assignments Practice Location: 4402 E 9 Mile Rd, Warren, MI 48091 Phone: 586-200-0611 Fax: 586-381-7055 | |
Andre Louis Rowlett, MD General Practice Medicare: Not Enrolled in Medicare Practice Location: 11477 East 12 Mile Road, Warren, MI 48093 Phone: 586-751-0200 Fax: 586-751-0414 | |
Albert Spickers, General Practice Medicare: Not Enrolled in Medicare Practice Location: 26193 Meredith Drive, Warren, MI 48091 Phone: 313-841-0395 Fax: 313-841-0580 | |
Nicole Marie Janowicz, D.O. General Practice Medicare: Not Enrolled in Medicare Practice Location: 12000 E 12 Mile Rd, Warren, MI 48093 Phone: 586-576-4140 Fax: 586-576-4146 |